Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BRAF inhibitor
Pharma
Day One pressures Novartis with FDA nod for novel RAF inhibitor
Compared with Novartis' BRAF offering, Day One's Ojemda covers a broader patient population in pediatric low-grade glioma.
Angus Liu
Apr 23, 2024 10:13pm
Pfizer takes on Novartis with FDA nod for lung cancer combo
Oct 12, 2023 10:10am
Novartis' targeted cancer combo wins tumor-agnostic FDA nod
Jun 23, 2022 8:15am
